Exchange: NASDAQ·Updated 07:30 PM EST
CLDX logo

CLDX Celldex Therapeutics Inc.

$27.40
$0.54
(1.93%)
Today
Closed $27.42
$0.02
(0.07%)
After Hours
Reported EarningsNov 5
Mkt Cap$2.15B
Vol1.72M

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
60

Bullish Sentiment

How do you feel about CLDX?

FactsPlease99
$CLDX Increases price target to $64 from $42 yesterday. That is some confidence.... what does he know...
4
Rayvio_News_Filter
$CLDX 🏥 Celldex Therapeutics, Inc. reported topline Phase 2 results showing barzolvolimab did not meet key efficacy measures or its internal hurdle rate for continued development in atopic dermatitis. Market-relevant event
3
lucabrix
$CLDX Several Wall Street analysts rushed to Celldex's defense, claiming expectations were low for the study and that its failure is "immaterial" to the investment case in the company. The "key debate" ahead for Celldex is barzolvolimab's place in the "growing" market for chronic spontaneous urticaria treatments, wrote Stifel analyst Alex Thompson.
2
lucabrix
$CLDX “Celldex is leading the exploration of mast cell science to understand the contribution of mast cells to various diseases and how targeted mast cell depletion can best be implemented to improve the lives of patients,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. “We have delivered best in disease data in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism while also increasing our understanding of which diseases, like atopic dermatitis, might not be primarily driven by mast cells.
1
lucabrix
$CLDX Systemic mast cell depletion observed, consistent with prior studies, as evidenced by significant reduction in serum tryptase Favorable safety and tolerability demonstrated, consistent with prior studies BLA submission for barzolvolimab in CSU anticipated in 2027 Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling Additional indications for barzolvolimab to be announced by year end
1

Advertisement|Remove ads.